Story Feb. 6 - X4 Pharmaceuticals ... Story Feb. 5 - Viracta Therapeutics: The cancer biotech has closed its doors, laying off all employees and winding down operations. Story Feb. 5 - Frontier ...

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “sell (d-)” rating reiterated by stock analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Janux Therapeutics has a twelve month low of $29.63 and a twelve month high of $71.71. The stock has a fifty day simple moving average of $41.27 and a 200 day simple moving average of $47.48.

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half ...

March 10 (Reuters) - India's Sun Pharmaceutical Industries (SUN.NS), opens new tab said on Monday it will acquire Checkpoint Therapeutics (CKPT.O), opens new tab, a U.S.-based immunotherapy and ...

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...

Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product ...

Fast-Track Your mRNA-Based Therapeutics & Vaccines from Discovery to Commercialisation by Ensuring Targeted Delivery, Durability & Tolerable Immunogenicity Across All Disease Indications As mRNA ...